EU/3/16/1703

About

On 14 July 2016, orphan designation (EU/3/16/1703) was granted by the European Commission to TMC Pharma Services Ltd, United Kingdom, for setmelanotide for the treatment of pro-opiomelanocortin deficiency.

The sponsorship was transferred to TMC Pharma (EU) Limited, Ireland, in March 2019.

The sponsorship was transferred to Rhythm Pharmaceuticals Limited, Ireland, in November 2020.

Key facts

Active substance
Setmelanotide
Disease / condition
Treatment of pro-opiomelanocortin deficiency
Date of first decision
14/07/2016
Outcome
Positive
EU designation number
EU/3/16/1703

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Rhythm Pharmaceuticals Limited
10 Earlsfort Terrace 
Dublin 2  
D02 T380 
Co. Dublin 
Ireland
E-mail: regulatory.services@tmcpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating